What podcasts say about Vlad Schwarz

Every statement, with the speaker, the exact quote and the moment it was said.

What Vlad Schwarz has said on podcasts

9 statements · 7 positive · 1 negative · 1 neutral

on TinnitusNegativeJan 15, 2026· Mad Money w/ Jim Cramer
Tinnitus affects up to 50 million Americans and lacks approved drug therapy
“tinnitus affects up to 50 million Americans, and there's no approved drug therapy”
Listen at 29:57
Open the episode · Mad Money w/ Jim Cramer 1/14/26
on T-alphaPositiveJan 15, 2026· Mad Money w/ Jim Cramer
Biohaven’s T-alpha reduces fat while increasing skeletal muscle mass
“it directly... reduces fat, but importantly, it increases skeletal muscle mass.”
Listen at 31:32
Open the episode · Mad Money w/ Jim Cramer 1/14/26
on T-alpha obesity trialNeutralJan 15, 2026· Mad Money w/ Jim Cramer
Biohaven’s T-alpha obesity trial will report results in 2026
“We already initiated an important phase three trial in obesity. It's reading out this year.”
Listen at 31:40
Open the episode · Mad Money w/ Jim Cramer 1/14/26
on Biohaven obesity and precision-immunology programsPositiveJan 15, 2026· Mad Money w/ Jim Cramer
Biohaven’s focused obesity and immunology investments may benefit patients and investors
“we think there's going to be upside for patients and investors.”
Listen at 32:03
Open the episode · Mad Money w/ Jim Cramer 1/14/26
on Biohaven degrader technologyPositiveJan 15, 2026· Mad Money w/ Jim Cramer
Biohaven’s degrader technology selectively removes disease-causing blood pathogens
“we're able to target disease-causing pathogens in your blood and degrade them and not touch anything else.”
Listen at 32:18
Open the episode · Mad Money w/ Jim Cramer 1/14/26
on Biohaven degrader for IgA nephropathyPositiveJan 15, 2026· Mad Money w/ Jim Cramer
Biohaven’s degrader may substantially improve treatment for IgA nephropathy
“we think this is going to be a game changer for people suffering from IgA nymphopathy.”
Listen at 32:58
Open the episode · Mad Money w/ Jim Cramer 1/14/26
on Biohaven precision-immunology platformPositiveJan 15, 2026· Mad Money w/ Jim Cramer
Biohaven is pursuing additional autoimmune disease indications
“there's a number of other autoimmune diseases that we're going after”
Listen at 33:17
Open the episode · Mad Money w/ Jim Cramer 1/14/26
on BiohavenPositiveJan 15, 2026· Mad Money w/ Jim Cramer
Biohaven believes it can compete successfully against larger drug companies
“We think we can do it again.”
Listen at 33:53
Open the episode · Mad Money w/ Jim Cramer 1/14/26
on Biohaven KV7 activatorsPositiveJan 15, 2026· Mad Money w/ Jim Cramer
Biohaven’s KV7 activators may treat epilepsy with fewer side effects
“we can treat epilepsy without the burden of all the side effects.”
Listen at 35:43
Open the episode · Mad Money w/ Jim Cramer 1/14/26

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.